Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Hugo J. A. Adams & Thomas C. Kwee. (2018) Interim FDG-PET/CT in Hodgkin lymphoma: what are we actually looking at?. Acta Oncologica 57:8, pages 1128-1130.
Read now
Read now
Cheng-Cheng Liao, Yun-Ying Qin, Xiao-Hong Tan, Jia-Jie Hu, Qi Tang, Yan Rong, Hong Cen & Le-Qun Li. (2017) Predictive value of interim PET/CT visual interpretation in the prognosis of patients with aggressive non-Hodgkin’s lymphoma. OncoTargets and Therapy 10, pages 5727-5738.
Read now
Read now
Articles from other publishers (18)
Joel Wight, Shin Hnin Wai, Edward Shen, Sze‐Ting Lee, Salvatore Berlangieri, Tineke Fancourt, Eliza Hawkes, Anthony Hannah, Teresa Leung & Geoffrey Chong. (2021) Predicting primary treatment failure using interim FDG‐PET scanning in diffuse large B‐cell lymphoma. European Journal of Haematology 107:4, pages 475-483.
Crossref
Crossref
Lale Kostakoglu, Maurizio MartelliLaurie H. SehnDavid BeladaAngelo-Michele CarellaNeil ChuaEva Gonzalez-Barca, Xiaonan HongAntonio Pinto, Yuankai Shi, Yoichi TatsumiAndrea KnappFederico MattielloTina NielsenDeniz SahinGila SellamMikkel Z. OestergaardUmberto Vitolo & Marek Trněný. (2021) End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. Blood Advances 5:5, pages 1283-1290.
Crossref
Crossref
Emanuele Zucca, Luciano Cascione, Teresa Ruberto, Davide Facchinelli, Sämi Schär, Stefanie Hayoz, Stefan Dirnhofer, Luca Giovanella, Mario Bargetzi, Christoph Mamot & Luca Ceriani. (2020) Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B‐cell lymphoma: post‐hoc analysis from the SAKK38/07 clinical trial. Hematological Oncology 38:5, pages 715-725.
Crossref
Crossref
Luca Ceriani, Giuseppe Gritti, Luciano Cascione, Maria Cristina PirosaAngela PolinoTeresa RubertoAnastasios StathisAndrea BrunoAlden A. MocciaLuca Giovanella, Stefanie Hayoz, Sämi SchärStefan DirnhoferAlessandro Rambaldi, Giovanni MartinelliChristoph Mamot & Emanuele Zucca. (2020) SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. Blood Advances 4:6, pages 1082-1092.
Crossref
Crossref
Lale Kostakoglu & Grzegorz S. Nowakowski. (2019) End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma. PET Clinics 14:3, pages 307-315.
Crossref
Crossref
Luis O�ate‑Oca�a, Violeta Cort�s, Rodrigo Castillo‑Llanos, Andrea Terrazas, Osvaldo Garcia‑Perez, Quetzalli Pital�a‑Cortes, Mayra Ponce, Alfonso Due�as‑Gonzalez & Myrna Candelaria. (2018) Metabolic tumor volume changes assessed by interval 18fluorodeoxyglucose positron emission tomography‑computed tomography for the prediction of complete response and survival in patients with diffuse large B‑cell lymphoma. Oncology Letters.
Crossref
Crossref
Hugo J. A. Adams & Thomas C. Kwee. (2017) The Deauville criteria cannot differentiate between responding and non-responding non-Hodgkin lymphoma patients. Annals of Hematology 97:4, pages 719-720.
Crossref
Crossref
Hugo J.A. Adams & Thomas C. Kwee. (2017) An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma. Seminars in Oncology 44:6, pages 404-419.
Crossref
Crossref
Hugo J. A. Adams & Thomas C. Kwee. (2017) Interim FDG-PET in lymphoma, a questionable practice in hematology. European Journal of Nuclear Medicine and Molecular Imaging 44:12, pages 2014-2017.
Crossref
Crossref
Lan V. Pham, Jerry L. Bryant, David Yang & Richard J. Ford. 2017. Personalized Pathway-Activated Systems Imaging in Oncology. Personalized Pathway-Activated Systems Imaging in Oncology
17
42
.
Hugo J.A. Adams & Thomas C. Kwee. (2016) Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: Systematic review and meta-analysis. European Journal of Radiology 85:11, pages 1963-1970.
Crossref
Crossref
Renata de Oliveira Costa, Abrahão Hallack Neto, Sheila Siqueira, Luis Alberto de Padua Covas Lage, Henrique M. de Paula, Arthur M. Coutinho & Juliana Pereira. (2016) Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era. Nuclear Medicine Communications 37:10, pages 1095-1101.
Crossref
Crossref
Daniel Spira, Leonard Grünwald, Wichard Vogel, Alexander Sauter, Sven Michael Spira, Claus Detlef Claussen & Marius Horger. (2014) Midtreatment Evaluation of Lymphoma Response to Chemotherapy by Volume Perfusion Computed Tomography. Journal of Computer Assisted Tomography 38:1, pages 123-130.
Crossref
Crossref
Ukihide Tateishi. (2013) PET/CT in malignant lymphoma: basic information, clinical application, and proposal. International Journal of Hematology 98:4, pages 398-405.
Crossref
Crossref
Martin Allen-Auerbach, Sven de Vos & Johannes Czernin. (2013) PET/Computed Tomography and Lymphoma. Radiologic Clinics of North America 51:5, pages 833-844.
Crossref
Crossref
C. Furth, A. S. Erdrich, I. G. Steffen, J. Ruf, M. Stiebler, D. Kahraman, C. Kobe, S. Schönberger, R. Grandt, P. Hundsdoerfer, K. Hauptmann, H. Amthauer & H. Hautzel. (2017) Interim PET response criteria in paediatric non-Hodgkin’s lymphoma. Nuklearmedizin 52:04, pages 15-20.
Crossref
Crossref
Christian Furth, Ingo G Steffen, Anne S Erdrich, Patrick Hundsdoerfer, Juri Ruf, Günter Henze, Stefan Schönberger, Holger Amthauer & Hubertus Hautzel. (2013) Explorative analyses on the value of interim PET for prediction of response in pediatric and adolescent non-Hodgkin lymphoma patients. EJNMMI Research 3:1, pages 71.
Crossref
Crossref
Yuyuan Zhu, Jianda Lu, Xin Wei, Shaoli Song & Gang Huang. (2013) The Predictive Value of Interim and Final [18F] Fluorodeoxyglucose Positron Emission Tomography after Rituximab-Chemotherapy in the Treatment of Non-Hodgkin's Lymphoma: A Meta-Analysis. BioMed Research International 2013, pages 1-8.
Crossref
Crossref